1. Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

    Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

    Rubius Therapeutics Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
  2. Topics Mentioned